oMass Therapeutics

oMass Therapeutics is a biotechnology company focused on discovering and developing innovative small molecule therapeutics for rare diseases and immunological conditions. The company utilizes its proprietary OdyssION™ platform, which combines native mass spectrometry, biochemistry, and custom chemistry to interrogate drug targets within their native ecosystems, such as membrane proteins and intracellular complexes, enabling the targeting of proteins previously considered 'undruggable'. Headquartered in Oxford, UK, the company was spun out of the University of Oxford based on research from the laboratory of Professor Dame Carol Robinson. oMass operates with a strategy of developing its own pipeline for specialty immunology and rare disease indications while entering into strategic collaborations with major pharmaceutical companies for broader indications.